2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece
Thessaloniki, 546 21, Greece
NCT Number: NCT02725879
It is well documented that thyroid hormones (THs) are involved in energy and lipid metabolism, thermogenesis, and body weight control, acting on several tissues. Thus, any change in thyroid status may affect body weight and metabolic rate. On the other hand, fibroblast growth factor 21 (FGF-21) is a complex hormone involved in energy, lipid, and glucose metabolism, sharing common biochemical pathways and sites of action with THs. FGF-21 is synthesized and acts primarily on the liver, but weaker expression has also been described in muscle, pancreas, and adipose tissue. In addition, FGF-21 acts through endocrine and paracrine mechanisms, regulating metabolic pathways such as fatty acid oxidation, glucose uptake, and thermogenesis. Recent animal and human studies have highlighted a close bidirectional relationship between FGF-21 and THs, partially elucidated. Thyroid hormones regulate the expression of the FGF-21 gene in the liver and can also increase FGF-21 levels in vivo. However, it has also been suggested that some of their key actions are largely independent. Data on FGF-21 levels and their metabolic role in pediatric patients with chronic autoimmune thyroiditis (AIT) are scarce. This study aims to measure FGF-21 serum levels in children and adolescents with Hashimoto's thyroiditis and investigate any possible associations between FGF-21 serum levels and resting metabolic rate (RMR) and levothyroxine (LT4) treatment, or other clinical and biochemical parameters.
Looking for future studies?
Notify Me5 year–18 year
All sexes
Observational
Thessaloniki, 546 21, Greece
Children and adolescents, aged 5-18 years, will undergo routine screening for chronic autoimmune thyroiditis (AIT) at the Pediatric Endocrinology Outpatient Clinic of "Papageorgiou" General Hospital and "AHEPA" University Hospital of Thessaloniki, Greece. The diagnosis of AIT will be based on the presence of anti-thyroid autoantibodies (Anti-TPOAb and/or Anti-TgAb) and one or more of the following: clinical symptoms of thyroid dysfunction, goiter, or diffuse/irregular hypoechogenicity of the thyroid gland during an ultrasound examination.
All participants should have a normal body mass index (BMI) for their age and sex, be drug-naive for at least 3 months, follow no special diet, and have no chronic and/or acute disease or menstrual disorder. Only those subjects that will start routine LT4 treatment will be reassessed at six months (not the rest participants), with no specific intervention to take place during those six months.
For all participants, a detailed medical history will be recorded. The following parameters will be measured and calculated: age and pubertal stage according to Tanner, height, body weight, Body Mass Index (BMI), waist circumference, hip circumference, mid-upper arm circumference (MUAC), and skinfolds measurement in order to estimate the percentage of body fat (%BF). The resting metabolic rate (RMR) will be measured with a portable device applying indirect calorimetry. Blood samples will be collected after overnight fasting.
The following parameters will be tested in serum: thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase antibody (Anti-TPOAb) titers, thyroglobulin antibody (Anti-TgAb) titers, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), γglutamyltransferase (γ-GT), alkaline phosphatase (ALP), applying an automatic chemical analyzer or immunoassay system and analogs reagents that already exist at the hospital. Serum FGF-21 levels will be determined in pg/mL using the Solid Phase Sandwich Enzyme-linked Immunosorbent Assay (ELISA) method according to the manufacturer's protocol.
Additionally, all participants, with the help of their parents and/or caregivers, will complete the Mediterranean Diet Index (KIDMED) at their first visit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For patients
For Controls:
Exclusion criteria
For patients
For Controls:
Time frame: baseline and 6 months
serum fibroblast growth factor 21 (FGF-21) levels after an overnight fasting
Time frame: baseline and 6 months
Resting Metabolic Rate (RMR) per kilogram of body weight per day
Time frame: baseline and 6 months
Standard Deviation Score (SDS) for Body Mass Index (BMI). The standard deviation is a measure of the amount of variation or spread of a set of values around the mean or average. The mean or average value is given an SDS of "0". A negative SDS indicates that the value is below the average or mean and a positive value means it is above the average or mean. SDS correspond to growth chart percentiles as follow:
-2.68 = 0.4th percentile, -2.01 = 2nd percentile, -1.34 = 9th percentile, -0.67 = 25th percentile, 0 (mean or average) = 50th percentile, +0.67 = 75th percentile, +1.34 = 91st percentile, +2.01 = 98th percentile, +2.68 = 99.6th percentile.
These percentiles help us understand whether a measurement falls within the normal range for children of the same age and sex. A lower SDS value (closer or lower to -2.68) and a higher SDS value (closer or above +2.68) mean a worst outcome, while a SDS value closer to 0 (mean or average), mean a better outcome.
Time frame: baseline and 6 months
Waist Circumference
Time frame: baseline and 6 months
Hip circumference
Time frame: baseline and 6 months
mid-upper arm circumference
Time frame: baseline and 6 months
Body fat percentage (%BF), is the total mass of fat divided by total body mass. The total body fat includes essential body fat and stored body fat.
Time frame: baseline and 6 months
Fat mass index (FMI) is calculated by dividing the fat weight in kilograms by the height in metres squared.
Time frame: baseline and 6 months
Fat free mass index (FFMI) is calculated by dividing the free fat weight in kilograms by the height in metres squared.
Time frame: baseline and 6 months
thyroid-stimulating hormone (TSH) after an overnight fasting
Time frame: baseline and 6 months
free triiodothyronine after an overnight fasting
Time frame: baseline and 6 months
free thyroxine (FT4) after an overnight fasting
Time frame: baseline and 6 months
glucose serum level after an overnight fasting
Time frame: baseline and 6 months
insulin serum level after an overnight fasting
Time frame: baseline and 6 months
Total Cholesterol (TC) serum level after an overnight fasting
Time frame: baseline and 6 month
Triglyceride (TG) serum level after an overnight fasting
Time frame: baseline and 6 months
high-density lipoprotein (HDL) serum level after an overnight fasting
Time frame: baseline and 6 months
low-density lipoprotein (LDL) serum level after an overnight fasting
Time frame: baseline and 6 months
aspartate aminotransferase (AST) serum level after an overnight fasting
Time frame: baseline and 6 months
alanine aminotransferase (ALT) serum level after an overnight fasting
Time frame: baseline and 6 months
gamma gloutamyltransferase (γ-GT) serum level after an overnight fasting
Time frame: baseline and 6 months
alkaline phosphatase (ALP) serum level after an overnight fasting
Time frame: baseline and 6 months
HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance, using fasting insulin and blood glucose levels after an overnight fastιng. The meaningful part of the acronym is "insulin resistance". It marks for both the presence and extent of any insulin resistance that you might currently express. It is a way to reveal the dynamic between the baseline (fasting) blood sugar and the responsive hormone insulin.
Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.
Time frame: baseline
Mediterranean diet index (KIDMED) score is a questionnaire used to evaluate adherence to the Mediterranean diet in children and adolescents. The KIDMED assesses how well an individual's dietary habits align with the Mediterranean diet.
Scoring System: 16 questions, each associated with a specific value. The total score ranges from -4 to 12.
Interpretation:
≤3: Very-low-quality diet. 4-7: Need to improve the food pattern to align with the Mediterranean diet.
≥8: Optimal adherence to the Mediterranean diet. A lower overall score (≤3) mean a worst outcome (adherence); while a higher overall score (≥8) mean a better outcome (adherence).
Time frame: baseline
specific foods frequency consumption based on the KIDMED questionnaire
Time frame: baseline and 6 months
antithyroid peroxidase antibody (Anti-TPOAb) titers
Time frame: baseline and 6 months
thyroglobulin antibody (Anti-TgAb) titers
Aristotle University Of Thessaloniki
Other
Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.
Acronym: THYROMETABOL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07652450
Adenocarcinoma, Adenocarcinoma, Follicular
Minya, Minya Governorate, Egypt
View Trial DetailsNCT05949671
Autoimmune Diseases, Endocrine System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05077865
Autoimmune Diseases, Endocrine System Diseases
Clearwater, Florida, United States
View Trial DetailsNCT04682340
Autoimmune Diseases, Endocrine System Diseases
Krakow, Malopolska, Poland
View Trial Details